Publications by authors named "John R. Fawcett"
Intracerebroventricular injection of insulin-like growth factor (IGF)-I has been shown to protect against stroke in rats. This method of delivery is not practical in human beings, as it requires an operation with risk of infection and other complications. Intranasal (i.
View Article and Find Full Text PDFArticle Synopsis
- Arachidonic acid (AA) acts as a reversible inhibitor of muscarinic acetylcholine receptors (mAChRs) and its effects on ligand binding were studied across various receptor types.
- AA inhibited binding to all mAChR subtypes, the beta2-adrenergic receptor, 5-hydroxytryptamine receptor, and micro-opioid receptor, while having no effect on the nicotinic receptor, even at high concentrations.
- The findings suggest that AA significantly impacts multiple G protein-coupled receptors (GPCRs), highlighting the need for further research to understand the inhibition mechanisms involved.
Oxidative stress has been implicated as a contributing factor to neurodegeneration in Alzheimer's disease. An endogenous, low molecular weight (LMW) inhibitor from Alzheimer's brain inactivates the human brain muscarinic acetylcholine receptor (mAChR). The inhibitor prevents agonist and antagonist binding to the mAChR as assessed by radioligand binding studies.
View Article and Find Full Text PDFPurpose: To assess the potential of delivering nerve growth factor (NGF) to the brain along the olfactory neural pathway for the treatment of Alzheimer's disease. Methods: Recombinant human NGF (rhNGF) was given as nose drops to anesthetized rats. The rhNGF concentrations in the brain were determined by enzyme-linked immunosorbent assay (ELISA).
View Article and Find Full Text PDF